Qiagen announces FDA clearance for QIAstat-Dx Meningitis/Encephalitis Panel
The Fly

Qiagen announces FDA clearance for QIAstat-Dx Meningitis/Encephalitis Panel

Qiagen (QGEN) announced that the FDA has cleared the QIAstat-Dx Meningitis/Encephalitis Panel for clinical use. This marks the fourth QIAstat-Dx syndromic test to receive U.S. regulatory clearance in 2024.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App